Overview

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

Status:
Not yet recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The objective of this research is to find out what effects (good and bad), the combination of gemcitabine and nab-paclitaxel therapy (GEM-ABR for the rest of the document), standard chemotherapy for pancreatic cancer, and the TheraBionic device has on participants' condition.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
Therabionics
Treatments:
Gemcitabine
Paclitaxel